AHL Partners LLP raised its position in CONMED Corporation (NASDAQ:CNMD) by 2,792.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,090 shares of the medical technology company’s stock after purchasing an additional 152,624 shares during the quarter. AHL Partners LLP owned about 0.57% of CONMED Corporation worth $8,053,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of CONMED Corporation by 46,036.5% during the first quarter. BlackRock Inc. now owns 3,153,427 shares of the medical technology company’s stock valued at $140,043,000 after buying an additional 3,146,592 shares during the last quarter. Champlain Investment Partners LLC boosted its position in shares of CONMED Corporation by 16.4% during the first quarter. Champlain Investment Partners LLC now owns 1,728,445 shares of the medical technology company’s stock worth $76,760,000 after buying an additional 243,610 shares during the period. Epoch Investment Partners Inc. bought a new position in CONMED Corporation in the 1st quarter worth approximately $9,447,000. Heartland Advisors Inc. grew its holdings in CONMED Corporation by 315.7% in the 2nd quarter. Heartland Advisors Inc. now owns 165,992 shares of the medical technology company’s stock worth $8,456,000 after buying an additional 126,062 shares in the last quarter. Finally, Macquarie Group Ltd. grew its holdings in CONMED Corporation by 15.5% in the 1st quarter. Macquarie Group Ltd. now owns 674,656 shares of the medical technology company’s stock worth $29,961,000 after buying an additional 90,685 shares in the last quarter. Institutional investors own 98.32% of the company’s stock.

Shares of CONMED Corporation (CNMD) traded up 0.90% during mid-day trading on Wednesday, hitting $53.76. 3,709 shares of the stock were exchanged. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 96.17 and a beta of 0.68. The company’s 50-day moving average is $50.34 and its 200-day moving average is $49.40. CONMED Corporation has a 1-year low of $37.60 and a 1-year high of $54.12.

CONMED Corporation (NASDAQ:CNMD) last released its earnings results on Wednesday, July 26th. The medical technology company reported $0.41 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.41. The company had revenue of $197.20 million during the quarter, compared to analysts’ expectations of $194.50 million. CONMED Corporation had a return on equity of 8.38% and a net margin of 2.02%. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period last year, the firm earned $0.47 EPS. Equities research analysts anticipate that CONMED Corporation will post $1.87 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 5th. Stockholders of record on Friday, September 15th will be paid a $0.20 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.50%. CONMED Corporation’s dividend payout ratio (DPR) is presently 142.86%.

Several analysts recently commented on the company. BidaskClub cut CONMED Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Needham & Company LLC reiterated a “buy” rating and set a $57.00 price target on shares of CONMED Corporation in a research report on Friday, September 1st. KeyCorp reiterated a “hold” rating on shares of CONMED Corporation in a research report on Friday, August 25th. Zacks Investment Research cut CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Finally, TheStreet raised CONMED Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $49.33.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at http://www.mareainformativa.com/ahl-partners-llp-has-8-05-million-holdings-in-conmed-corporation-cnmd/115268/.

In related news, Director Jo Ann Golden sold 3,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the sale, the director now owns 19,782 shares of the company’s stock, valued at approximately $989,100. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.62% of the company’s stock.

CONMED Corporation Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Institutional Ownership by Quarter for CONMED Corporation (NASDAQ:CNMD)

Receive News & Stock Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related stocks with our FREE daily email newsletter.